EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies

Juan Morote iD, Berta Miró iD, Lucas Regis iD, François Cousin iD, Patrick Duflot iD, Philippe Kolh iD, Alice Andalò iD, Nicola Gentili, Filippo Merloni iD, Andrea Prochowski Iamurri iD, Fabio Ferroni iD, Enrique Trilla iD and 1 more

BJUI Compass · 2026-04 · 7 (4)

DOI: 10.1002/bco2.70198 ↗

At a glance

Journal article in BJUI Compass, published online on 2026-04-10. Written by Juan Morote and 12 co-authors. Institution: Department of Surgery Universitat Autònoma de Barcelona Bellaterra Spain. Cited 3 times so far (Crossref); 9 references. The full text is freely available (open access, CC BY 4.0).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Early detection of significant prostate cancer (sPCa) has notably improved with the widespread use of magnetic resonance imaging (MRI) and targeted biopsies. This advancement has contributed to the recommendation for PCa screening in the European Union. Nevertheless, PCa suspicion is still primarily based on a serum prostate-specific antigen (PSA) level greater than 3.0 ng/mL and/or a suspicious digital rectal examination (DRE). Prostate MRI is then requested to identify lesions suspected of harbouring sPCa, particularly when the Prostate Imaging-Reporting and Data System (PI-RADS) score is above 2. In such cases, both targeted biopsies of suspicious lesions and systematic biopsies are recommended, whereas prostate biopsy is typically avoided when the PI-RADS score is below 3. The European Association of Urology recommends the use of predictive models to reduce unnecessary prostate biopsies and the over-detection of insignificant prostate cancer (iPCa), especially in uncertain scenarios as PI-RADS 3 where the mean rate of sPCa detection is 20% and the overdetection of iPCa remains up to 50%.1 Accessible web- or smartphone-based risk calculators are essential for integrating predictive models into routine practice for assessing individual sPCa likelihood. Furthermore, validating these predictive models in populations different from those used in their development is crucial to ensure generalizability and clinical reliability.2 The Barcelona MRI predictive model (BCN-MRI PM) was developed at a single academic institution within 1487 men suspected of having PCa, drawn from the sPCa opportunistic early detection program of Catalonia between 2016 and 2019. Two- to four-core MRI-transrectal ultrasound fusion targeted biopsies of PI-RADS lesions >2 and/or 12-core systematic biopsies when PI-RADS

Subjects

Author keywords

early detectionfederated networkpredictive modelssignificant prostate cancervalidation

Authors and institutions

  • Department of Surgery Universitat Autònoma de Barcelona Bellaterra Spain.
  • Department of Urology Vall d'Hebron University Hospital Barcelona Spain.
  • Research Group of Urology Vall d'Hebron Research Institute Barcelona Spain.
  • Statistics Unit Vall d'Hebron Research Institute Barcelona Spain.
  • Department of Oncological Imaging Liège University Hospital Liège Belgium.
  • Department of Medical Information Systems Liège University Hospital Liège Belgium.

ORCID profiles: Juan Morote, Berta Miró, Lucas Regis, François Cousin, Patrick Duflot, Philippe Kolh, Alice Andalò, Filippo Merloni, Andrea Prochowski Iamurri, Fabio Ferroni, Enrique Trilla

Cite

APA

Morote, J., Miró, B., Regis, L., Cousin, F., Duflot, P., Kolh, P., Andalò, A., Gentili, N., Merloni, F., Iamurri, A. P., Ferroni, F., Trilla, E., & Méndez, O. (2026). European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies. BJUI Compass, 7(4). https://doi.org/10.1002/bco2.70198

Vancouver

Morote J, Miró B, Regis L, Cousin F, Duflot P, Kolh P, et al. European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies. BJUI Compass. 2026;7(4). doi:10.1002/bco2.70198

BibTeX
@article{Morote2026,
  author = {Morote, Juan and Miró, Berta and Regis, Lucas and Cousin, François and Duflot, Patrick and Kolh, Philippe and Andalò, Alice and Gentili, Nicola and Merloni, Filippo and Iamurri, Andrea Prochowski and Ferroni, Fabio and Trilla, Enrique and Méndez, Olga},
  title = {European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies},
  journal = {BJUI Compass},
  year = {2026},
  volume = {7},
  number = {4},
  doi = {10.1002/bco2.70198}
}
Start for free →